Analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post earnings of $2.47 per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $2.37 and the highest estimate coming in at $2.61. Alexion Pharmaceuticals reported earnings of $2.02 per share during the same quarter last year, which indicates a positive year over year growth rate of 22.3%. The firm is expected to issue its next quarterly earnings report on Wednesday, October 23rd.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year earnings of $9.90 per share for the current financial year, with EPS estimates ranging from $9.72 to $10.31. For the next fiscal year, analysts anticipate that the company will report earnings of $10.74 per share, with EPS estimates ranging from $9.18 to $12.31. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.51. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. Alexion Pharmaceuticals’s revenue was up 15.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.07 EPS.
In other Alexion Pharmaceuticals news, insider Aradhana Sarin sold 578 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $132.00, for a total transaction of $76,296.00. Following the sale, the insider now directly owns 30,201 shares in the company, valued at approximately $3,986,532. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Indrani Lall Franchini sold 4,500 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the sale, the executive vice president now owns 29,627 shares in the company, valued at $3,933,873.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 428,567 shares of company stock worth $53,420,869. 4.08% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Investors Research Corp purchased a new stake in shares of Alexion Pharmaceuticals in the 1st quarter valued at approximately $27,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $28,000. Redhawk Wealth Advisors Inc. purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Ossiam purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $32,000. Finally, Thor Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 1st quarter valued at approximately $34,000. Institutional investors own 93.77% of the company’s stock.
NASDAQ:ALXN opened at $111.47 on Friday. The company has a quick ratio of 3.56, a current ratio of 4.04 and a debt-to-equity ratio of 0.26. The firm has a market cap of $24.99 billion, a price-to-earnings ratio of 15.72, a price-to-earnings-growth ratio of 1.05 and a beta of 1.65. The company has a 50-day moving average price of $120.35. Alexion Pharmaceuticals has a 1-year low of $92.56 and a 1-year high of $141.86.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Article: Leveraged Buyout (LBO) Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.